EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate
Portfolio Pulse from Vandana Singh
SAB Biotherapeutics (NASDAQ:SABS) plans to raise up to $130 million through a private placement of preferred stock. The proceeds will fund the company through 2026 and advance the development of SAB-142, its lead therapeutic candidate for type 1 diabetes. The transaction is led by RA Capital Management, with participation from several other investors.
October 02, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SAB Biotherapeutics is raising up to $130M via preferred equity, which will fund the company and advance its lead diabetes candidate. This could potentially boost investor confidence.
The news of SAB Biotherapeutics raising funds to advance its lead diabetes candidate is directly related to the company and its future prospects. This could potentially boost investor confidence and have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100